Skip to main content
vial

Glenmark launches vancomycin hydrochloride for injection

Vancomycin Hydrochloride for Injection had a market value of approximately $39.3 million for the 12-month period ending January 2025, per IQVIA.
Levy

Glenmark is introducing vancomycin hydrochloride for injection, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), which is the generic of Mylan’s Vancomycin Hydrochloride for Injection.

Vancomycin Hydrochloride for Injection had a market value of approximately $39.3 million for the 12 month period ending January 2025, per IQVIA.

[Read more: Glenmark releases generic Travatan Z]

Marc Kikuchi, president and business head, North America at Glenmark, said, "We are excited to announce the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial), adding another quality product to our institutional portfolio."

[Read more: Glenmark debuts Olopatadine Hydrochloride Ophthalmic Solution OTC]

X
This ad will auto-close in 10 seconds